RxDoctor Payments Data

Melinda Smith, MD

Cardiovascular Disease · Greenville, SCNPI 1922084086

Payments from drug & device makers

$1,712in general payments, 2019–2025

Across 55 payments — averaging $31.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$439
  • Novartis$201
  • Boston Scientific$145
  • Edwards Lifesciences$119
  • Abiomed$107
  • Kiniksa Pharmaceuticals International, PLC$91
  • plus $609 from 15 others

What the payments were for

  • Food & beverage$1,712100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,712 in reported general payments places this provider in the 25th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$124,594
Medicare patients
1,084
Services billed
2,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban309$318,601
Repatha SureclickEvolocumab71$76,123
XareltoRivaroxaban40$41,714
EntrestoSacubitril/Valsartan16$24,388
Metoprolol Succinate268$3,083
Valsartan93$2,729
Atorvastatin Calcium195$2,186
Rosuvastatin Calcium103$1,504
Flecainide Acetate28$1,414
Carvedilol121$1,208
Torsemide72$971
Losartan Potassium103$917
Amlodipine Besylate143$900
Isosorbide Mononitrate ErIsosorbide Mononitrate36$825
Diltiazem 24hr Er (Cd)Diltiazem Hcl27$767

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$318,601309 claims
Johnson & JohnsonXarelto$39$41,71440 claims
NovartisEntresto$201$24,38816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →